# Dennis McWilliams > Dennis McWilliams is a Series A investor at SparkMed Advisors backing Health Care and Medical. See 12 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [SparkMed Advisors](https://shizune.co/investors/profile/sparkmed-advisors) - Location: Austin, United States - Total investments: 12 - Last investment: Jul 2026 - Lead investor: 92% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/dennismcwilliams/ Dennis McWilliams is a Partner at Sante Ventures. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Health Care | 5 | 42% | | Medical | 4 | 33% | | Biotechnology | 3 | 25% | | Artificial Intelligence | 3 | 25% | | Software | 2 | 17% | 16 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 8 | 67% | | Seed | 2 | 17% | | Series B | 1 | 8% | ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 7 | 58% | | Japan | 1 | 8% | | Canada | 1 | 8% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | RapidPulse | RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $48M | Series B | Jul 16, 2026 | | | SONIRE Therapeutics | SONIRE Therapeutics is a clinical-stage medical device company. It is a U.S. subsidiary of SONIRE Therapeutics Co., Ltd.. | $18M | Series A | Apr 15, 2026 | | | Sonire Therapeutics | SONIRE Therapeutics Inc. (SONIRE) is working on a next-generation high-intensity focused ultrasound (HIFU) therapy system that will employ acoustic engineering (ultrasound) technologies developed through cutting-edge academic research. SONIRE has been working on a next-generation high-intensity focused ultrasound (HIFU) treatment system as a noveltherapeutic modality with the goal of giving cancer patients and their families a new future. | $18M | Series A | Apr 15, 2026 | | | OutcomesAI | OutcomesAI operates as a healthcare company, that combines AI Voice Agents with licensed nurses to deliver safe, scalable care across health systems. | $10M | Seed | Oct 14, 2025 | | | BeeKeeperAI | BeeKeeperAI is a zero trust collaboration platform protecting both algorithm IP and regulated data. | $12.1M | Series A | Jun 27, 2023 | | | Surgical Safety Technologies Inc. | Surgical Safety Technologies delivers data-driven AI technology to hospitals for safe surgeries. It empowers surgeons with an objective assessment of technical and non-technical proficiency using academically validated frameworks. | $15M | Series A | May 04, 2023 | | | RapidPulse | RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $10.6M | Series A | Aug 31, 2022 | | | RapidPulse | RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry | $15M | Series A | Jun 23, 2021 | | | Nirogy Therapeutics | Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncologyas well as autoimmune diseases. | $16.5M | Series A | Jan 26, 2021 | | | KelaHealth | KelaHealth Surgical Intelligence Platform delivers patient-specific predictive insights and recommended interventions at key decision points to improve surgical care quality and clinical operations. It is creating a learning ecosystem to improve surgical care outcomes. | $2.9M | Seed | Oct 28, 2020 | | 10 of 12 investments shown. ## Co-investors - [Epidarex Capital](https://shizune.co/investors/profile/epidarex-capital) — VC Fund, 3 deals together - [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 3 deals together - [SBI Investment](https://shizune.co/investors/profile/sbi-investment-2) — VC Fund, 3 deals together - [Syntheon](https://shizune.co/investors/profile/syntheon) — VC Fund, 3 deals together - [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures) — VC Fund, 2 deals together - [Fast Track Initiative, Inc.](https://shizune.co/investors/profile/fast-track-initiative) — VC Fund, 2 deals together ## About SparkMed Advisors VC Fund 1 contacts available at SparkMed Advisors. | Name | Title | Profile | | --- | --- | --- | | Dennis McWilliams | Managing Director | https://shizune.co/investors/profile/dennis-mcwilliams | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ## FAQ ### What does Dennis McWilliams invest in? Dennis McWilliams invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Seed stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Dennis McWilliams last invest? The most recent investment recorded for Dennis McWilliams closed in Jul 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co